Registered title, quoted from ClinicalTrials.gov
AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP
An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by Union Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07933757, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Hepatic dysfunction, defined as alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal (ULN).
Exclusion criterion 3
Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m².
Exclusion criterion 4
Thrombocytopenia, defined as a platelet count of less than 100 × 10⁹/L.
Exclusion criterion 6
Anemia, defined as a hemoglobin level of less than 90 g/L.
Exclusion criterion 8
Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07933757, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Volunteer to participate, understand and sign an informed consent form.
- Age ≥ 18 years old, regardless of gender.
- Patient diagnosed with coronary heart disease requiring percutaneous coronary intervention.
- Complete all planned percutaneous coronary intervention during hospitalization.
- Patient must be treated according to national guidelines for standard treatment of coronary heart disease.
Exclusion Criteria:
- Known hypersensitivity or allergy to colchicine, eplerenone, leflunomide, or artesunate.
- Use of colchicine, eplerenone, leflunomide, or artesunate within 30 days before screening.
- Hepatic dysfunction, defined as alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal (ULN).
- Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m².
- Hyperkalemia, defined as a serum potassium level greater than 5.0 mmol/L.
- Thrombocytopenia, defined as a platelet count of less than 100 × 10⁹/L.
- Leukopenia, defined as a white blood cell count of less than 3.0 × 10⁹/L.
- Anemia, defined as a hemoglobin level of less than 90 g/L.
- Requirement for potassium supplementation or potassium-sparing diuretics, including amiloride, spironolactone, triamterene, etc.
- Current treatment with potent CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, etc.
- Uncontrolled infectious diseases.
- Known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor, etc.
- Current or planned use of medications outside the study protocol that may affect immune or inflammatory responses, including nonsteroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids, immunomodulatory agents, chemotherapeutic agents, etc.
- Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives.
- Any other circumstances in which the investigator judges that the patient is not suitable to participate in the study.
Quoted from ClinicalTrials.gov, NCT07933757, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07933757, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.